← Leaderboards
Jason Douglas Salter
Oyagen, Inc.
$871,862
Attributed
$871,862
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $299K · FY2020–23$500K$375K$250K$125K$0
'20
'21
'22
'23
Funding mix
By agency
NIH$871,862 · 2
By mechanism
R43$871,862 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Preclinical Development”
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Julie Ake · National Institute Of Allergy And Infectious Diseases$52,642,120
- Prasant Mohapatra · University Of California At Davis$51,108,355
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$43,147,107
- Urs Ochsner · Crestone, Inc.$40,390,611
Research focus
Preclinical DevelopmentScreeningIn VitroPharmaceutical PreparationsProtein Protein InteractionReporterInfectionInnovationMutantPharmaceutical ChemistryDrug DiscoveryPropertyAntiviral AgentsProteinsDoseIndexingCritical PathwaysComplexLeadCytotoxicityParticleCellsDrug CandidateSmall Molecule
Grant awards (3)
High throughput screening and drug discovery for antagonists of the Ebola VP40 protein assembly$299,000
R43 · FY2023 · AI · contact PI
Development of Lead Inhibitors of HIV Vif Binding to Antiretroviral A3G Through Medicinal Chemistry$286,431
R43 · FY2021 · AI · contact PI
Development of Lead Inhibitors of HIV Vif Binding to Antiretroviral A3G Through Medicinal Chemistry$286,431
R43 · FY2020 · AI · contact PI